20. March 2025
The RNhale GmbH, an LMU spin-off, has received 2.5 million euros in funding from the European Innovation Council (EIC). The company will use the funds to further work on the realization of a drug for the treatment of asthma.
19. March 2025
Das Startup Epicure wurde bei den Academy Days von Science4Life als eines von 5 Startups mit dem Science4Life Venture Cup ausgezeichnet.
18. September 2023
QuGen GmbH, founded by Thomas carell and Pascal Giehr, provides high-sensitive long read sequencing (PacBio), bisulfite-free sequencing of DNA methylation and mass spectrometry quantification of non-canonical nucleobases in DNA and RNA. This includes also sample preparation and data analysis. With this QuGen fulfills unmet needs in quantification and positional information of epigenetic nucleobases.
Dr Daniel Andergassen received an ERC Starting Grant for his research on the molecular causes of gender-specific differences in heart failure.
25. October 2023
September 2023
Prof Baer de Oliveira Mann received an ERC Starting Grant for her NTase Pro project.
On May 1, the Cluster for Nucleic Acid Therapeutics Munich (CNATM) started its work.
CNATM is an innovation network of science and industry, which is funded with five million euros annually by the federal government, the Free State of Bavaria and participating companies. The research network consists of scientists from the leading universities LMU and TUM. The universities of Regensburg and Würzburg, the Helmholtz Center Munich and 17 companies from the region around Munich are also involved. A total of 22 applications were awarded funding, marking the start of the Nucleic Acid Isar Valley.
The multilateral collaborations of CNATM are creating a network from which novel nucleic acid-based drugs and next-generation vaccines will be developed. Recent discoveries give rise to the hope that the ability to design nucleic acids in a highly specific and theoretically predictable way will open up completely new therapeutic approaches in medicine and thus help many people. There is no substance class that is better suited to personalized medicine than nucleic acids. The Future Cluster wants to help nucleic acid therapies achieve a breakthrough and thus make a contribution that makes sense: curing people and creating jobs in and around Munich.
We are very happy, to be one of only 7 clusters4future in Germany and the only one in Bavaria of the second round of the competition.
Our thanks go to all members and partner companies who made this possible.
The LMU spin-off Eisbach Bio GmbH was mentioned Handelsblatt as one of the top 5 promising biotech companies in Germany. They were mentioned particularly frequently by leading venture capitalists when it comes to promising projects in early research phases.
LMU spin-off Eisbach Bio GmbH has received a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant will support the clinical development of EIS-12656, which targets challenging cancers with homologous recombination defects (HRD). Eisbach Bio GmbH had previously secured $4.5 million in funding in June 2024. Juni 2024 4,5 Mio $ Fördermittel gesichert.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information